2024 Mahindra Thar ROXX, Features Monroe OE Solutions Dampers with Next-Generation Rebound Stop Technology
The new Thar ROXX, unveiled in Kochi on 15th August 2024, offers an unmatched blend of sophistication, performance, presence, safety, and technology. Positioned as ''THE' SUV,' the five-door model is a fully capable on- and off-road SUV that comfortably seats five. With its All-New M_GLYDE Platform, it is engineered for a smooth ride and precise handling, ensuring class-leading dynamics on and off the road. To ensure exceptional ride and handling performance in all driving conditions, Mahindra and Mahindra selected Monroe OE Solutions double-tube dampers featuring the next-generation Ride Refine AHRS, a highly tunable secondary valve that works in concert with each damper's main valve to absorb peak loads during high-energy bumps and when encountering deep potholes. This unique capability ensures optimal energy absorption to decrease body control without compromising passenger comfort.
'Ride Refine AHRS technology delivers premium damping performance and an exceptionally broad tuning range,' said Hal Zimmermann, Vice President and General Manager, Monroe Ride Solutions. 'Our growing portfolio of Ride Refine secondary valve systems opens the door to a vast new range of ride tuning and performance capabilities available through conventional passive dampers.'
The new Ride Refine AHRS features an innovative pressure tube and a proprietary high strength sealing ring that provide a smooth and progressive transition to hydraulic rebound stop activation. The system allows OEMs to deliver a comfortable ride in all vehicles, but especially in SUVs.
Each OE Solutions damper on the Thar ROXX also features the Monroe MTV CL piston valve, providing digressive damping characteristics for enhanced handling performance, and the Ride Refine RC1 valve, which applies frequency dependent damping to smooth out high-frequency wheel motions.
Tenneco is one of the world's leading designers, manufacturers, and marketers of automotive products for original equipment and aftermarket customers. Through our DRiV, Performance Solutions, Clean Air and Powertrain business groups, Tenneco is driving advancements in global mobility by delivering technology solutions for light vehicle, commercial truck, off-highway, industrial, motorsport and the aftermarket.
Visit www.tenneco.com to learn more.
About Mahindra
Founded in 1945, the Mahindra Group is one of the largest and most admired multinational federation of companies with 260000 employees in over 100 countries. It enjoys a leadership position in farm equipment, utility vehicles, information technology and financial services in India and is the world's largest tractor company by volume. It has a strong presence in renewable energy, agriculture, logistics, hospitality, and real estate. The Mahindra Group has a clear focus on leading ESG globally, enabling rural prosperity and enhancing urban living, with a goal to drive positive change in the lives of communities and stakeholders to enable them to Rise. Learn more about Mahindra on www.mahindra.com / Twitter and Facebook: @MahindraRise / For updates subscribe to https://www.mahindra.com/news-room
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lung Cancer Screening Market to Reach USD 7.44 Billion by 2032, Driven by LDCT Adoption and Growing High-Risk Population
Global Lung Cancer Screening Market Forecast (2025–2032) Shows 9.32% CAGR, U.S. Market to Hit USD 2.21 Billion by 2032 Amid Early Detection Demand and Technological Advancements. Austin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lung Cancer Screening Market Size & Growth Analysis: According to SNS Insider, The Lung Cancer Screening Market was estimated at USD 3.66 billion in 2024 and is expected to reach USD 7.44 billion by 2032, at a CAGR of 9.32% during the forecast period of 2025-2032. The global lung cancer screening market growth is driven by the increasing prevalence of lung cancer and growing adoption of screening, initiatives to increase awareness about lung cancer, and the introduction of new and advanced products. Favorable governmental policies, rising healthcare infrastructure, and technological advancements are other factors driving Free Sample Report of the Lung Cancer Screening Market: The U.S. lung cancer screening market was estimated at USD 1.12 billion in 2024 and is expected to reach USD 2.21 billion by 2032, at a CAGR of 8.89% during the forecast period of 2025-2032 The U.S. dominated the North American lung cancer screening market, driven by robust policy support and early uptake of low-dose computed tomography (LDCT) among the eligible high-risk population of 50 to 80-year-olds with a smoking history of 20+ pack-years under updated USPSTF guidelines. Segmentation & Regional Highlights By Modality, the LDCT Segment Dominates the Lung Cancer Screening Market in 2024 The low-dose computed tomography (LDCT) segment held the largest share of the lung cancer screening market in 2024 with a 61.2% market share owing to high accuracy, non-invasive nature, and support by such as the U.S. Preventive Services Task Force (USPSTF) and other major health societies. LDCT allows early lung cancer diagnosis in high-risk patients and dramatically improves survival. Incorporation of cancer screening and insurance coverage has facilitated adoption, particularly in the developed world. By Cancer Type, the Non-Small Cell Lung Cancer (NSCLC) Segment Dominates the Market and is Witnessing High Growth Over the Forecast Period Non-small cell lung cancer (NSCLC) segment held a major share of the lung cancer screening market in 2024 as a result of the high prevalence of NSCLC among the population, which accounts for nearly 85% of all lung cancer cases around the globe. NSCLC is slow compared to small cell lung cancer, making it possible for more cases to be found early and diagnosed during screening. The demand for NSCLC screening has also increased with the development of targeted therapies and biomarkers for NSCLC. The 60–69 Years Segment Dominated the Lung Cancer Screening Market by Age Group The 60–69 years age group dominated the Lung Cancer Screening Market in the year 2024, owing to the higher prevalence of lung cancer in this age group. Members of this group are usually longer-term smokers or have had more exposure to carcinogens, and are therefore at higher risk, justifying the need for regular screening. Many countries' medical guidelines give this age range priority for low-dose CT screening, which has driven an increase in use. Lung Cancer Screening Market in North America Led in 2024 with a 40.3% Market Share, APAC Poised to be the Fastest-Growing Regional Market. The lung cancer screening market in North America is driven by the well-developed healthcare system, early uptake of advanced screening technologies such as LDCT, and favorable reimbursement scenarios. Marked awareness of lung cancer, full-scale enforcement of national screening guidelines, and a strong position of key players provide additional prospects for regional supremacy. Screening programmes promoted by governmental institutions such as the U.S. Preventive Services Task Force (USPSTF) have increased the screening rates, especially in high-risk individuals, and the region has evolved into a global market leader. The Asia-Pacific lung cancer screening market is estimated to register the highest CAGR, on account of a rise in the incidence of lung cancer, increasing awareness, and the increasing healthcare expenditure in the region. China, India, Japan, and other countries are enhancing early cancer screening initiatives, expanding access to LDCT and biomarker testing. For a Personalized Briefing with Our Industry Analysts, Connect Now: Key Lung Cancer Screening Companies Profiled in the Report GE HealthCare Siemens Healthineers Philips Healthcare Canon Medical Systems Corporation Fujifilm Holdings Corporation Samsung Medison Co. Ltd. Carestream Health Shimadzu Corporation Vuno Inc. Zebra Medical Vision Aidoc Riverain Technologies Lunit Inc. Roche Diagnostics Illumina Inc. Guardant Health Exact Sciences Corporation Bio-Rad Laboratories CT Screening International and other players. Lung Cancer Screening Market Report Scope Report Attributes Details Market Size in 2024 US$ 3.66 billion Market Size by 2032 US$ 7.44 billion CAGR CAGR of 9.32% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Key Growth Drivers Growing incidence of lung cancer worldwide Increased public awareness and government-led screening programs Advancements in imaging technologies (e.g., AI-enabled CT scans) Rising demand for non-invasive and early-stage cancer detection Supportive reimbursement policies in the U.S. and Europe Unique Selling Propositions (USPs) of the Report: Country-level eligibility for the screening landscape Assists your company in prioritizing markets that have high potential opportunity by comparing age, risk, and reimbursement criteria for screening across countries. Adoption curves comparison: LDCT vs. new technologies Facilitates strategic planning by identifying lung cancer screening early adopters vs. laggards for LDCT and next-gen technologies, and helps to launch market entry timing. Biomarker Inclusion in Lung Screening Helps companies make R&D and partnership decisions by monitoring how molecular diagnostics are supplementing or undercutting traditional screening. RoS (Return on Screening) Modelling Measures the cost per site of value of your screening programs to enable XYZ Company to create a persuasive business case for customers or reimbursement agencies, or health authorities. Buy the Full Lung Cancer Screening Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare
Dubai, UAE,, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As UAE healthcare and financial institutions race to meet stringent ADHICS regulations, MIT Consultants emerges as a trusted advisor, guiding enterprises toward robust compliance through tailored cybersecurity solutions. The cybersecurity landscape in the UAE has dramatically evolved, with healthcare and financial institutions facing heightened regulatory demands under the Abu Dhabi Healthcare Information and Cyber Security Standards (ADHICS). Recent high-profile data breaches and cyber threats have highlighted the urgent need for organizations to comply fully with these standards, protecting sensitive patient and financial information. As organizations scramble to adapt, MIT Consultants, a Dubai-based cybersecurity advisory and solutions reseller, is becoming a pivotal player in assisting healthcare and financial institutions in navigating the complexities of ADHICS compliance. Expert Advisors, Tailored Solutions MIT Consultants differentiates itself through its vendor-neutral advisory approach, ensuring that the solutions recommended are best suited to each organization's specific operational and compliance needs. Rather than advocating for a particular product, the firm's cybersecurity experts thoroughly analyze an institution's existing infrastructure, identify vulnerabilities, and align their recommendations precisely with ADHICS requirements. "Our role goes beyond mere reselling of cybersecurity solutions," says Mohamed Moussous, CEO of MIT Consultants. "We see ourselves as strategic partners. Our clients benefit from our ability to pinpoint precisely what's needed to achieve compliance efficiently and securely." Addressing Critical Cybersecurity Needs Healthcare and financial institutions face particular vulnerabilities—ransomware, phishing attacks, insider threats—all of which ADHICS compliance seeks to mitigate through rigorous cybersecurity measures. MIT Consultants addresses these threats by implementing robust Privileged Access Management (PAM), real-time threat detection systems, patch management processes, and secure information management strategies tailored specifically to ADHICS regulations. Real-World Successes MIT Consultants has successfully guided numerous institutions through ADHICS compliance by identifying gaps, providing detailed roadmaps, and recommending integrated solutions from global cybersecurity vendors. Their expertise ensures minimal operational disruption while achieving full regulatory adherence, ultimately safeguarding institutions from both cyber threats and potential regulatory penalties. "With our deep understanding of the UAE cybersecurity landscape, we provide not just technical solutions but peace of mind," adds Moussous. "Our clients trust us because we have their best interests at heart, which is compliance, security, and operational efficiency." A Strategic Advantage In an environment where regulatory compliance and cybersecurity intersect critically, MIT Consultants offers UAE healthcare and financial institutions a significant strategic advantage. By entrusting compliance initiatives to specialized cybersecurity advisors, organizations can stay ahead of threats, ensure adherence to regulations, and maintain a secure operational environment. As ADHICS continues to shape the future of cybersecurity compliance in the UAE, MIT Consultants stands out as an indispensable ally, turning complex regulatory challenges into clear, actionable strategies. Mohamed Moussous, CEO of MIT ConsultantsIRIS BAY - Business Bay Dubai Website: of the Group : CONTACT: mmoussous@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
BioTalent Canada Earns National DEI Honour for Third Year—Continues to Raise the Bar in Workplace Inclusion
OTTAWA, Ontario--(BUSINESS WIRE)--BioTalent Canada has once again been named a 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter. This recognition underscores the organization's leadership in fostering inclusive workplace practices and driving change across Canada's bio-economy. 'Our IDEA strategy isn't just a framework—it's something we try to live every day.' Selected as one of 14 winners, BioTalent Canada stands out for embedding IDEA—Inclusion, Diversity, Equity and Accessibility— into every aspect of its operations. The national award celebrates employers that are not only making meaningful internal change but also setting the tone for others in their sector. 'Our IDEA strategy isn't just a framework—it's something we try to live every day,' says Rob Henderson, President and CEO of BioTalent Canada. 'We're proud to be recognized for our efforts, but prouder to represent a best practice for Canada's bio-economy.' An internal employee engagement survey conducted in 2025 revealed that: 94% of staff reported that BioTalent Canada follows through on its IDEA commitments. 97% felt the organization is an inclusive workplace where people of all different backgrounds, cultures and beliefs are treated fairly. 100% of staff reported feeling welcome and included in BioTalent Canada's culture. BioTalent Canada's commitment to IDEA extends beyond its own team. As a national workforce development council, the organization equips small and medium-sized enterprises (SMEs) with practical, evidence-based tools to help them compete for talent and build inclusive workplace cultures. According to BioTalent Canada's national labour market intelligence report, Canada's bio-economy will require 65,000 new workers by 2029—a demand many SMEs struggle to meet. To support employers, BioTalent Canada offers: The I.D.E.A.L. Bioscience Employer™ Recognition Program, which helps build employer brand and credibility An employer resource toolkit to help integrate IDEA into recruitment, onboarding and retention BioTalent Canada's award-winning approach to IDEA extends beyond its internal practices and employer supports—it also reaches the next generation of talent. In 2024, the organization launched the I.D.E.A.L. Scholarship™, providing financial support to Indigenous students and persons with disabilities entering their first year of a bioscience post-secondary program. In 2025, the scholarship was expanded to include newcomers to Canada, reinforcing BioTalent Canada's long-term commitment to removing barriers and creating a more equitable, diverse talent pipeline for the bio-economy. 'Our goal is to build a bio-economy where every employer—regardless of size or resources—can compete for talent, foster innovation and create welcoming workplaces,' adds Henderson. 'This award reflects our belief that IDEA represents not only a values-based choice, but a competitive advantage.' To learn more about the I.D.E.A.L. Bioscience Employer Recognition Program, visit Is it important for your organization to stay updated on the latest HR trends and practices? Contact Soufiane at info@ to find out how BioTalent Canada can help. Rob Henderson is available for comment. About BioTalent Canada BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy stakeholders with evidence-based data and industry-driven standards. BioTalent Canada, as a workforce development council, is focused on igniting the industry's brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada's most vital sectors. BioTalent Canada has received varied distinctions following a thorough and independent analysis of the organization. By practicing the same industry standards it recommends to partners, the organization has been honored with the following titles: Great Place to Work ® since 2019 and one of the Best Workplaces in Healthcare for 2023 by Great Place to Work Canada ® The Best Leader in Diversity, Equity, and Inclusion at the 2024 Best Ottawa Business Awards 2024 Collaboration Catalyst by Magnet Network One of Canada's Best Places to Work by HRD Canada for 2024 5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter since 2023 For more information, visit To determine the companies with the most effective DE&I programs, Canadian HR Reporter first invited organizations to participate by filling out an employer form, which asked them to explain their diversity and inclusion initiatives and practices. Next, employees from nominated companies were asked to fill out an anonymous form evaluating their workplace on a number of metrics. To be considered, each organization had to reach a minimum number of employee responses based on overall size. Organizations that achieved an 80 per cent or greater average satisfaction rating from employees were named 5-Star Diversity, Equity and Inclusion Employers for 2025. For more information, visit
